Technologies related to NCATS

Custom text
BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
Ref: NCI-E-009-2010 | Updated: 06/04/2021
BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
Ref: E-009-2010 | Updated: 06/04/2021
COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)
Ref: TAB-3428 | Updated: 06/04/2021
Targeting Heparan Sulfate-dependent Viral Entry As A Therapeutic Option For COVID-19
Ref: E-006-2021-0 | Updated: 06/04/2021
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Ref: E-105-2019 | Updated: 06/04/2021
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Ref: NCI-E-105-2019 | Updated: 06/04/2021
Autophagy Modulators For Use in Treating Cancer
Ref: E-003-2018 | Updated: 06/04/2021
Autophagy Modulators For Use in Treating Cancer
Ref: NCI-E-003-2018 | Updated: 06/04/2021
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
Ref: TAB-2887 | Updated: 06/04/2021
Development Of A Novel Class Of Compounds In Treatment Of Hepatitis C
Ref: E-161-2014-0 | Updated: 06/08/2021
Potential New Drugs for Treating or Preventing Pruritus
Ref: TAB-3266 | Updated: 06/04/2021
Blockage Of NPR1 Receptor For Treatment Of Itch
Ref: E-485-2013-1 | Updated: 06/08/2021
Blockage Of NPR1 Receptor For Treatment Of Itch
Ref: E-485-2013-2 | Updated: 06/08/2021
Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors
Ref: TAB-3244 | Updated: 06/04/2021
Small Molecule Inhibitors Of Aldehyde Dehydrogenase 1A1 (ALDH1A1)
Ref: E-101-2017-0 | Updated: 06/08/2021
Niclosamide for Treating Adrenocortical Cancer (ACC)
Ref: E-089-2016 | Updated: 06/04/2021
Niclosamide for Treating Adrenocortical Cancer (ACC)
Ref: NCI-E-089-2016 | Updated: 06/04/2021
Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors
Ref: E-115-2015 | Updated: 06/04/2021
Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors
Ref: NCI-E-115-2015 | Updated: 06/04/2021
Compounds That Treat Malaria and Prevent Malaria Transmission
Ref: TAB-2201 | Updated: 06/04/2021
Discovery Of Potential Antimalarial Drugs
Ref: E-283-2009-0 | Updated: 06/08/2021
Discovery Of Potential Antimalarial Drugs
Ref: E-283-2009-1 | Updated: 06/08/2021
Potent and Selective Cyclic Peptide Inhibitors of Phosphoglycerate Mutase as Anti-Infective Agents
Ref: TAB-3123 | Updated: 06/04/2021
Potent And Selective Cyclic Peptide Inhibitors Of Phosphoglycerate Mutase As Anti-infective Agents
Ref: E-229-2016-0 | Updated: 06/08/2021
Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus
Ref: TAB-2808 | Updated: 06/04/2021
Use Of Chlorcyclizine And Its Related Analogs In Treatment Of Hepatitis C
Ref: E-011-2014-0 | Updated: 06/08/2021
Novel Dopamine D2 Receptor Antagonists and Methods of Their Use
Ref: TAB-2813 | Updated: 06/04/2021
Selective Human D2 Dopamine Receptor Antagonists As Potential Antipsychotic Agents
Ref: E-030-2013-0 | Updated: 06/08/2021
Use of Small Molecules to Treat PARP1-deficient Cancers
Ref: TAB-2870 | Updated: 06/04/2021
Use Of Small Molecules (UT2, C418 And Z26S) To Treat PARP1-deficient Cancers
Ref: E-039-2014-0 | Updated: 06/08/2021
Novel Small Molecule Antimalarials for Elimination of Malaria Transmission
Ref: TAB-2799 | Updated: 06/04/2021
Identification Of Novel Gametocytocidal Compounds
Ref: E-751-2013-0 | Updated: 06/08/2021
Biomarker For Diagnosis Of Hyposialylation Disorders And Prediction Of Treatment Efficacy
Ref: E-056-2013-0 | Updated: 06/08/2021
A Coincidence Reporter Gene-system For High Throughput Screening
Ref: E-300-2012-0 | Updated: 06/08/2021
Cotranslational Protein Expression System for High-throughput Screening
Ref: TAB-2608 | Updated: 06/04/2021
Pyruvate Kinase M2 Activators for the Treatment of Cancer
Ref: TAB-2564 | Updated: 06/04/2021
Small Molecule Activators Of The M2 Isoform Of Pyruvate Kinase
Ref: E-298-2011-1 | Updated: 06/08/2021
Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders
Ref: TAB-2554 | Updated: 06/04/2021
Tocopherol Analogues As Correctors Of Lysosomal Storage Disorders
Ref: E-148-2012-0 | Updated: 06/08/2021
Highly Potent and Selective Deubiquitinating Enzyme Inhibitor
Ref: TAB-2545 | Updated: 06/04/2021
Discovery Of Potent And Selective Inhibitors Of The USP1/UAF1 Deubiquitinase Complex
Ref: E-043-2013-0 | Updated: 06/08/2021
Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis
Ref: TAB-2517 | Updated: 06/04/2021
Discovery Of Docosahexaenoylamide Derivatives That Promote The Growth And Development Of Neurons
Ref: E-070-2012-0 | Updated: 06/08/2021
Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis
Ref: TAB-2498 | Updated: 06/04/2021
Selective And Potent Modulators Of The Relaxin Receptor 1 (RXFP1)
Ref: E-072-2012-0 | Updated: 06/08/2021
Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies
Ref: TAB-2493 | Updated: 06/04/2021
Cyclodextrins as Therapeutics for Lysosomal Storage Disorders
Ref: TAB-2494 | Updated: 06/04/2021
Non-inhibitory Chaperones Of Glucocerebrosidase
Ref: E-144-2012-0 | Updated: 06/08/2021
Non-inhibitory Chaperones Of Glucocerebrosidase
Ref: E-144-2012-1 | Updated: 06/08/2021
Non-inhibitory Chaperones Of Glucocerebrosidase
Ref: E-144-2012-2 | Updated: 06/08/2021
Uses Of Cyclodextrin And Cyclodextrin In Combination With Vitamin E For The Treatment Of All Lysosomal Storage Diseases
Ref: E-050-2012-0 | Updated: 06/08/2021
Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers
Ref: TAB-2383 | Updated: 06/04/2021
Human Galactokinase Inhibitors For The Treatment Of Galactosemia And Cancers
Ref: E-240-2011-0 | Updated: 06/08/2021
Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors
Ref: TAB-2373 | Updated: 06/04/2021
PNC Modulators For The Treatment Of Metastasis And Tumorgenesis
Ref: E-276-2011-0 | Updated: 06/08/2021
Novel Compounds For Treatment Of Giardiasis
Ref: E-211-2010-2 | Updated: 06/08/2021
Methods of Treating Giardiasis Using FDA-Approved Compounds
Ref: TAB-2307 | Updated: 06/04/2021
Novel Compounds For Treatment Of Giardiasis
Ref: E-211-2010-1 | Updated: 06/08/2021
Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease
Ref: TAB-2263 | Updated: 06/04/2021
Novel Thio-ether Analogues As A Treatment For Huntington's Disease
Ref: E-258-2010-0 | Updated: 06/08/2021
Glucocerebrosidase Activators as a Treatment for Gaucher Disease
Ref: TAB-2252 | Updated: 06/04/2021
Glucocerebrosidase Activators As A Treatment For Gaucher Disease
Ref: E-257-2010-0 | Updated: 06/08/2021
Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting
Ref: TAB-2224 | Updated: 06/04/2021
Discovery Of Selective 12-human Lipoxygenase Inhibitors For The Treatment Of Diabetes And Prevention Of Platelet-mediated Clot Formation Caused By Cardiovascular Disease
Ref: E-134-2010-0 | Updated: 06/08/2021
Pyruvate Kinase M2 Activators for the Treatment of Cancer
Ref: TAB-2202 | Updated: 06/04/2021
Substituted 3-oxo-3,4-dihydroquinoline-2H-benzo [b] [1,4] Oxazine-7-sulfonamides And 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides Small Molecule Activators Of Human Pyruvate Kinase
Ref: E-120-2010-0 | Updated: 06/08/2021
Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases
Ref: TAB-2079 | Updated: 06/04/2021
Caspase 1 Inhibitor
Ref: E-308-2009-0 | Updated: 06/08/2021
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
Ref: TAB-1930 | Updated: 06/04/2021
Small Molecule Activators Of Human Pyruvate Kinase
Ref: E-326-2008-0 | Updated: 06/08/2021
Subscribe to Technologies related to NCATS